loading
Silexion Therapeutics Corp stock is traded at $0.97, with a volume of 273.24K. It is down -3.38% in the last 24 hours and up +7.82% over the past month. Silexion Therapeutics Corp a clinical-stage, oncology-focused biotechnology company engaged in the discovery and development of proprietary treatments for KRAS-driven cancers. The KRAS gene is an oncogene that is involved in the regulation of cell division as a result of its ability to relay external signals into the cell. Its product candidate, SIL204, consists of locally administered small interfering RNAs, or siRNA, in a solution, as a first-line treatment of locally advanced pancreatic cancer patients, or LAPC, in combination with standard-of-care chemotherapy. It is currently focused on treatment for pancreatic cancer tumors bearing the KRAS G12D or KRAS G12V mutations where metastases have not been detected and are non-resectable, i.e. it is not able to be surgically removed.
See More
Previous Close:
$1.01
Open:
$0.9584
24h Volume:
273.24K
Relative Volume:
0.06
Market Cap:
$8.48M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.0416
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
+6.00%
1M Performance:
+7.82%
6M Performance:
-61.95%
1Y Performance:
+0.00%
1-Day Range:
Value
$0.9408
$1.00
1-Week Range:
Value
$0.88
$1.09
52-Week Range:
Value
$0.575
$23.13

Silexion Therapeutics Corp Stock (SLXN) Company Profile

Name
Name
Silexion Therapeutics Corp
Name
Phone
972-8-6286005
Name
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Name
Employee
14
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
SLXN's Discussions on Twitter

Compare SLXN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
SLXN
Silexion Therapeutics Corp
0.9759 7.86M 0 -16.42M -6.75M -23.32
Biotechnology icon
ONC
Beigene Ltd Adr
239.94 25.61B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
444.16 114.83B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.30 41.82M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
590.71 66.38B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
73.56 6.36B 0 -153.72M -103.81M -2.00

Silexion Therapeutics Corp Stock (SLXN) Latest News

pulisher
May 26, 2025

Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World

May 26, 2025
pulisher
May 23, 2025

Silexion Therapeutics Receives Nasdaq Delisting Notice - TipRanks

May 23, 2025
pulisher
May 22, 2025

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - TradingView

May 22, 2025
pulisher
May 21, 2025

Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies Exploring Sil204's Potential Impact on Colorectal and Lung Cancer - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Silexion Completes Key Preclinical Studies for SIL204 - TipRanks

May 21, 2025
pulisher
May 21, 2025

Silexion Therapeutics Completes Key Preclinical Studies - GlobeNewswire

May 21, 2025
pulisher
May 21, 2025

Major Cancer Treatment Advance: Silexion's RNAi Drug Shows Promise Against 3 Deadly Cancers in $30B Market - Stock Titan

May 21, 2025
pulisher
May 13, 2025

Form 424B3 Silexion Therapeutics - StreetInsider

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy - Nasdaq

May 13, 2025
pulisher
May 13, 2025

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 13, 2025
pulisher
Apr 25, 2025

Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News

Apr 25, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa

Apr 23, 2025
pulisher
Apr 23, 2025

SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics enters collaboration with Catalent - TipRanks

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire

Apr 23, 2025
pulisher
Apr 23, 2025

Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan

Apr 23, 2025
pulisher
Apr 05, 2025

Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World

Apr 05, 2025
pulisher
Mar 31, 2025

Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech

Mar 31, 2025
pulisher
Mar 29, 2025

Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks

Mar 29, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Expands SIL204 Development Plan - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener

Mar 28, 2025
pulisher
Mar 28, 2025

Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan

Mar 28, 2025
pulisher
Mar 23, 2025

Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World

Mar 23, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion announces completion of expanded development plan for SIL204 - TipRanks

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire

Mar 21, 2025
pulisher
Mar 21, 2025

Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan

Mar 21, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Silexion Therapeutics Corp SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 17, 2025

Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan

Mar 17, 2025
pulisher
Mar 14, 2025

Silexion Therapeutics reaches deal to retire convertible note - Investing.com

Mar 14, 2025
pulisher
Mar 06, 2025

Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30% - DRP Journal

Mar 06, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer Models - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer - Benzinga

Mar 05, 2025
pulisher
Mar 05, 2025

Silexion Therapeutics Reports Positive Data for SIL204 - TipRanks

Mar 05, 2025

Silexion Therapeutics Corp Stock (SLXN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$1.15
price up icon 0.00%
$31.02
price down icon 0.96%
$579.77
price down icon 1.33%
$290.05
price up icon 0.45%
$4.28
price up icon 0.71%
$75.61
price up icon 0.73%
Cap:     |  Volume (24h):